Alectinib in Combination with Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided with Serum RNase1 and Tumor Expression of PD-L1

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 16, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 1, 2026

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Alectinib (Alecensa), Nivolumab (Opdivo)

Alectinib (Alecensa) in Combination with Nivolumab (Opdivo)

Trial Locations (1)

CMUH, Taichung

All Listed Sponsors

lead

China Medical University Hospital

OTHER